Forte Biosciences (FBRX) Projected to Post Earnings on Friday

Key Points

• Forte Biosciences is projected to release Q4 2025 results before the market opens on Friday, March 27, 2026, with analysts forecasting an EPS loss of ($1.42) and an earnings call scheduled for 4:00 PM ET.
• The stock opened at $24.61 (1‑year range $4.90–$35.62) with a market cap of about $308.4M, and analysts' consensus is a “Moderate Buy” with an average price target of $67.00.
• Forte is a clinical‑stage biotech developing topical live biotherapeutics—its lead candidate FB‑401 targets atopic dermatitis—and roughly 77.6% of shares are owned by institutional investors.

Forte Biosciences (NASDAQ:FBRX - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect Forte Biosciences to post earnings of ($1.42) per share for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Forte Biosciences Price Performance

Shares of NASDAQ FBRX opened at $24.61 on Friday. Forte Biosciences has a 1-year low of $4.90 and a 1-year high of $35.62. The company has a market capitalization of $308.36 million, a price-to-earnings ratio of -7.41 and a beta of 3.24. The business has a 50-day moving average of $29.94 and a 200-day moving average of $21.44.

Analysts Set New Price Targets

Several research firms recently commented on FBRX. Evercore assumed coverage on Forte Biosciences in a research report on Tuesday, November 25th. They set an "outperform" rating and a $65.00 price target on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Forte Biosciences in a research report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $67.00.

Institutional Trading of Forte Biosciences

Several large investors have recently modified their holdings of FBRX. Global Retirement Partners LLC acquired a new position in shares of Forte Biosciences in the fourth quarter worth about $27,000. Bank of America Corp DE grew its stake in Forte Biosciences by 5,641.8% during the 3rd quarter. Bank of America Corp DE now owns 3,158 shares of the company's stock valued at $47,000 after purchasing an additional 3,103 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Forte Biosciences during the 3rd quarter worth approximately $161,000. Jane Street Group LLC purchased a new stake in Forte Biosciences during the 4th quarter worth approximately $228,000. Finally, Citadel Advisors LLC acquired a new position in shares of Forte Biosciences in the 3rd quarter valued at approximately $234,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.